Evidence index
Go to the
original guidance.
Original research October 5, provider reviews October 15, and scientific sources October 21, 2026. Open current guidance when a question arises.
Sources and limits
Scientific sources checked October 21, 2026. Earlier research and provider sources retain their dated histories below. Federal sources provide general guidance; provider pages describe advertised terms. These sources do not assess an individual patient's situation.
- MedlinePlus — tirzepatide injection precautionsFederal patient drug information
- HRSA Poison Help — calling for expert guidanceFederal poison-response resource
- HRSA Poison Help — what you can doFederal emergency preparedness guidance
- FDA BeSafeRx — online pharmacy informationPharmacy verification and reporting resources
- CoreAge Rx — official treatment pagesProvider offer
- CoreAge Rx — tirzepatide offerProvider offer
- CoreAge Rx Help Center — Pricing & PlansProvider billing terms
- SuperHealthy Rx — current GLP-1 offerProvider offer
- Likeness Rx — GLP-1 plans and billingProvider offer
- Ro Body — membership and medication costsProvider offer
- WeightWatchers — Med+ membership and medicationProvider offer
- LillyDirect — pharmacy access and independent care optionsManufacturer access program
- FDA — concerns with unapproved GLP-1 drugsRegulator guidance
- FDA — compounding questions and answersRegulator guidance
- FDA — dosing errors with compounded injectable semaglutideSafety alert, July 2024
- NIDDK — prescription medications for overweight and obesityFederal patient education
- BeSafeRx: Frequently Asked Questions (FAQs)Primary health resource; checked October 5, 2026
- FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight LossPrimary health resource; checked October 5, 2026
- It can be a lifesaving tool, especially during an emergencyPrimary health resource; checked October 5, 2026
- What Should I Ask My Doctor During a Checkup?Primary health resource; checked October 5, 2026
- Medical Weight Loss Programs Available OnlineProvider public offer; checked October 5, 2026
- How It Works - PlushCareProvider public offer; checked October 5, 2026
- Online weight loss medication with or without insuranceProvider public offer; checked October 5, 2026
- Telehealth for Weight Loss, Hair Loss, Skin & More | Mochi HealthProvider public offer; checked October 5, 2026
- Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
- Henry | Personalized Weight Loss, Hormone & Sexual Health CareProvider public offer; checked October 5, 2026
- SlimShot: Current medical weight-management homepageProvider public information; checked October 15, 2026
- SlimShot: Separate public WL Meds order pageProvider public information; checked October 15, 2026
- SlimShot: Main-site terms of serviceProvider public information; checked October 15, 2026
- WL Meds: Terms linked from the SlimShot order page; November 22, 2023 PDFProvider public information; checked October 15, 2026
- Unique Physique: Public GLP-1 consultation pageProvider public information; checked October 15, 2026
- Unique Physique: Program prices and state exclusionsProvider public information; checked October 15, 2026
- Unique Physique: Consultation, renewal and cancellation policiesProvider public information; checked October 15, 2026
- Unique Physique: General terms and conditionsProvider public information; checked October 15, 2026
- Unique Physique: Operator and privacy informationProvider public information; checked October 15, 2026
- Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.Full primary post hoc analysis main text and main Table 1 reviewed; supplementary file and original trial protocols not independently reviewed. · Checked 2026-10-21
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.Full primary post hoc report, Methods, Results, main Table 1 and Discussion/funding reviewed; supplementary tables and source-trial protocols not separately reviewed. · Checked 2026-10-21
- DailyMed: WEGOVY semaglutide current prescribing informationCurrent official DailyMed label, updated June 18, 2026, current archive June 30, 2026; indications, relevant safety sections 5.2, 5.3, 5.5, 5.6, 5.10, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21
- DailyMed: ZEPBOUND tirzepatide current prescribing informationCurrent official DailyMed label, updated August 28, 2026, current archive September 2, 2026; indications, relevant safety sections 5.2 through 5.5 and 5.9, postmarketing experience and oral-drug interaction sections reviewed. Other sections not fully reviewed. · Checked 2026-10-21